Moderna, Inc. (MRNA)

All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has authorized its updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for individuals aged six months and older. Moderna is on track to deliver the updated vaccine in time for the 2025-2026 vaccination season.

CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences: Morgan Stanley's 23rd Annual Global Healthcare Conference, on Monday, September 8th at 10:00am ET Bernstein Insights: Healthcare Leaders and Disruptors, on Thursday, September 25th at 10:30am ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website. investors.modernatx.com.

Investing styles tend to evolve as people age. Seniors who are already retired often look for steady, reliable, dividend-paying companies.

View Preview

Since hitting their peak in late 2021, Moderna's (MRNA -1.69%) shares are down by more than 90%. The biotech company gained recognition by developing one of the leading coronavirus vaccines on the market, but its revenue and earnings subsequently plummeted as the pandemic waned.

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the biotechnology company's vaccines and said it would cancel some contracts and stop funding mRNA drug development.

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) net loss. MRNA stock has plummeted over 70% in the past year, reflecting investor concerns about ongoing losses and limited COVID vaccine demand. Despite recent approval of mNEXSPIRE, guidance suggests heavy 2025 losses, with management focused on downsizing and cost control.

Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.

MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.

Moderna, Inc. (NASDAQ:MRNA ) Q2 2025 Earnings Conference Call August 1, 2025 8:00 AM ET Company Participants James M. Mock - Chief Financial Officer Lavina Talukdar - Senior VP & Head of Investor Relations Stéphane Bancel - CEO & Director Stephen Hoge - President Conference Call Participants Courtney Breen - Sanford C.

Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares fell almost 9% in early trade as the pharmaceutical giant lowered its full-year guidance and announced a workforce reduction, overshadowing a Q2 earnings beat. The company lowered its 2025 revenue outlook by $300 million to a range of $1.5 billion to $2.2 billion, attributed to shipment timing.

Shares of Moderna (MRNA) fell sharply Friday after the company lowered the top end of its full-year revenue outlook because of a delay in vaccine deliveries to the UK.

Moderna has lowered the high end of its 2025 revenue forecast, citing a delay in Covid vaccine shipments to the UK. The company now expects between $1.5 billion and $2.2 billion in revenue, down $300 million at the top of its earlier range.

Moderna (MRNA) came out with a quarterly loss of $2.13 per share versus the Zacks Consensus Estimate of a loss of $2.99. This compares to a loss of $3.33 per share a year ago.

Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult decision but necessary step forward,” in an internal memo sent to employees on July 31.